Author

Roger Trinh

99.7% SUSTAINED VIROLOGIC RESPONSE RATE IN 369 HCV GENOTYPE 1B-INFECTED PATIENTS TREATED WITH LABEL-RECOMMENDED REGIMEN OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR WITH OR WITHOUT RIBAVIRIN

Jean-François Dufour, Heiner Wedemeyer, David E. Bernstein, Massimo Colombo, Manuel Romero-Gomez, Nancy Reau, Roger Trinh, Wangang Xie, Jeffrey Enejosa, Daniel E. Cohen, Marisol Martinez, Ira M. Jacobson

NORMALIZATION OF LIVER-RELATED LABORATORY PARAMETERS IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS AFTER TREATMENT WITH ABT-450/R/OMBITASVIR, DASABUVIR AND RIBAVIRIN

Stefan Zeuzem, Stanislas Pol, Marc Bourlière, Angeles Castro, Marina Berenguer, Sam Lee, Gregory Everson, Sandra Lovell, Marcos Pedrosa, Roger Trinh

SAFETY COMPARISON OF 12- AND 24-WEEK TREATMENTS IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS: RESULTS FROM TURQUOISE-II

Heiner Wedemeyer, Xavier Forns, Antonio Craxi, Paul Kwo, Stefan Bourgeois, Michael Bennett, Stephen Ryder, Dominique Larrey, David Mutimer, Sandra Lovell, Manal Abunimeh, Marcos Pedrosa, Roger Trinh

SUSTAINED VIROLOGIC RESPONSE RATE OF 96% IN HCV GENOTYPE 1A-INFECTED PATIENTS TREATED WITH OMBITASVIR/PARITAPREVIR/R AND DASABUVIR WITH RIBAVIRIN

Heiner Wedemeyer, Paul Pockros, Samuel S. Lee, Edward Gane, Christophe Moreno, Simone Strasser, Victor De Ledinghen, Andreas Maieron, Wangang Xie, Roger Trinh, Yan Luo, Fernando Tatsch, Vinod Rustgi

Item 1 - 4 / 4
1